Weekly Roundup: January 4-8, 2021

In case you missed it, some of this week’s featured content about expanding systemic therapies for psoriasis, new positive results from a phase 2 study investigating DAXI, guidance on COVID-19 vaccine side effects in dermal filler patients, new American Academy of Dermatology (AAD) and National Psoriasis Foundation (NPF) guidelines for psoriasis, plus more.

POLL: Do you incorporate antibiotics into your patients' acne treatment plan?

The Mainstream Patient: January 4

This week’s edition of The Mainstream Patient features stories on milia, alcohol in skincare, body acne, silicone sheet masks, plus more.

COVID-19 Induced Skin Challenges

Chief Medical Editor Zoe Diana Draelos, MD, discusses the challenges COVID-19 induces on the skin including chapped lips, maskne and dry hands from excessive hand washing.

Saving the world through pharmaceutical innovation

The COVID-19 vaccine, and the speed at which it was developed, is the medical breakthrough of our lifetimes.

Can doctors be expert witnesses against non-physicians?

In this month's Legal Eagle article, David J. Goldberg, MD, JD, examines the legality of whether physicians can be used as an expert witness against non-physicians.

New AAD-NPF psoriasis guidelines mark changes

New AAD-NPF guidelines focus on biologics, topical therapy, systemic non-biological therapies, management of pediatric patients, use of phototherapy and comorbidities.

DAXI demonstrates positive results in phase 2 study

Revance Therapeutics announces positive results from its phase 2 multicenter, open-label study investigating DaxibotulinumtoxinA (DAXI) as an injectable treatment for glabellar lines, lateral canthal lines and dynamic forehead lines.

Guidance issued for COVID-19 vaccine side effects in dermal filler patients

A new guidance from the American Society for Dermatologic Surgery (ASDS) has been released regarding side effects from the SARS-CoV-2 mRNA vaccine on dermal fillers.

Expanding line of therapeutic agents for psoriasis

Several systemic therapies are available for the treatment of patients with moderate to severe psoriasis. Continued research has further elucidated the immunopathogenesis of the disease, leading to the development of novel biologic agents that are proving to more effectively and safely address moderate to severe psoriatic lesions.